JP2007505149A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007505149A5 JP2007505149A5 JP2006526389A JP2006526389A JP2007505149A5 JP 2007505149 A5 JP2007505149 A5 JP 2007505149A5 JP 2006526389 A JP2006526389 A JP 2006526389A JP 2006526389 A JP2006526389 A JP 2006526389A JP 2007505149 A5 JP2007505149 A5 JP 2007505149A5
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- cycloalkyl
- cycloheteroalkyl
- prodrug
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 36
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims description 36
- 125000001072 heteroaryl group Chemical group 0.000 claims description 33
- 238000000034 method Methods 0.000 claims description 28
- 239000000651 prodrug Substances 0.000 claims description 28
- 229940002612 prodrug Drugs 0.000 claims description 28
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 27
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims description 24
- 125000000217 alkyl group Chemical group 0.000 claims description 22
- 229910052739 hydrogen Inorganic materials 0.000 claims description 22
- 239000001257 hydrogen Substances 0.000 claims description 22
- 125000003118 aryl group Chemical group 0.000 claims description 21
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 21
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 21
- 125000002252 acyl group Chemical group 0.000 claims description 18
- 125000004404 heteroalkyl group Chemical group 0.000 claims description 18
- 125000003107 substituted aryl group Chemical group 0.000 claims description 18
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical class NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims description 14
- 206010046543 Urinary incontinence Diseases 0.000 claims description 12
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 12
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 12
- 150000003839 salts Chemical class 0.000 claims description 9
- 239000012453 solvate Substances 0.000 claims description 9
- 229910052799 carbon Inorganic materials 0.000 claims description 6
- 125000004432 carbon atom Chemical group C* 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 125000003545 alkoxy group Chemical group 0.000 claims description 3
- 125000004429 atom Chemical group 0.000 claims description 3
- 125000005842 heteroatom Chemical group 0.000 claims description 3
- 229910052760 oxygen Inorganic materials 0.000 claims description 3
- 125000005415 substituted alkoxy group Chemical group 0.000 claims description 3
- 229910052717 sulfur Inorganic materials 0.000 claims description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 4
- 239000002552 dosage form Substances 0.000 claims 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 3
- -1 4- Imidazolylmethyl Chemical group 0.000 claims 2
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 claims 2
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 2
- 208000024891 symptom Diseases 0.000 claims 2
- 125000003143 4-hydroxybenzyl group Chemical group [H]C([*])([H])C1=C([H])C([H])=C(O[H])C([H])=C1[H] 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 206010066218 Stress Urinary Incontinence Diseases 0.000 claims 1
- 208000000921 Urge Urinary Incontinence Diseases 0.000 claims 1
- 239000011324 bead Substances 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 229960002870 gabapentin Drugs 0.000 claims 1
- 238000002513 implantation Methods 0.000 claims 1
- 238000001361 intraarterial administration Methods 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000007912 intraperitoneal administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 230000003902 lesion Effects 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 230000009245 menopause Effects 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 210000004877 mucosa Anatomy 0.000 claims 1
- 239000006186 oral dosage form Substances 0.000 claims 1
- 230000003204 osmotic effect Effects 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 239000006187 pill Substances 0.000 claims 1
- 229920000642 polymer Polymers 0.000 claims 1
- 229960001233 pregabalin Drugs 0.000 claims 1
- AYXYPKUFHZROOJ-ZETCQYMHSA-N pregabalin Chemical compound CC(C)C[C@H](CN)CC(O)=O AYXYPKUFHZROOJ-ZETCQYMHSA-N 0.000 claims 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 230000001568 sexual effect Effects 0.000 claims 1
- 208000022170 stress incontinence Diseases 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 238000013268 sustained release Methods 0.000 claims 1
- 239000012730 sustained-release form Substances 0.000 claims 1
- 230000009747 swallowing Effects 0.000 claims 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 230000001960 triggered effect Effects 0.000 claims 1
- 206010046494 urge incontinence Diseases 0.000 claims 1
- 0 COC(CC1(C*)CCCCC1)=* Chemical compound COC(CC1(C*)CCCCC1)=* 0.000 description 1
- 150000001204 N-oxides Chemical class 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US50258503P | 2003-09-11 | 2003-09-11 | |
| US50521003P | 2003-09-22 | 2003-09-22 | |
| US51228803P | 2003-10-17 | 2003-10-17 | |
| US53874804P | 2004-01-22 | 2004-01-22 | |
| PCT/US2004/029944 WO2005025562A1 (en) | 2003-09-11 | 2004-09-13 | Treating and/or preventing urinary incontinence using prodrugs of gaba analogs |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007505149A JP2007505149A (ja) | 2007-03-08 |
| JP2007505149A5 true JP2007505149A5 (https=) | 2007-09-13 |
Family
ID=34317683
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006526389A Pending JP2007505149A (ja) | 2003-09-11 | 2004-09-13 | ギャバ類似体のプロドラッグを用いる尿失禁の治療および／あるいは予防 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US7700652B2 (https=) |
| EP (1) | EP1670451A4 (https=) |
| JP (1) | JP2007505149A (https=) |
| KR (1) | KR20060119971A (https=) |
| AU (1) | AU2004272111A1 (https=) |
| CA (1) | CA2537837A1 (https=) |
| IL (1) | IL174409A0 (https=) |
| MX (1) | MXPA06002731A (https=) |
| NO (1) | NO20061625L (https=) |
| NZ (1) | NZ545884A (https=) |
| WO (1) | WO2005025562A1 (https=) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7186855B2 (en) | 2001-06-11 | 2007-03-06 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
| US8048917B2 (en) | 2005-04-06 | 2011-11-01 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
| US10675280B2 (en) | 2001-10-20 | 2020-06-09 | Sprout Pharmaceuticals, Inc. | Treating sexual desire disorders with flibanserin |
| UA78974C2 (en) | 2001-10-20 | 2007-05-10 | Boehringer Ingelheim Pharma | Use of flibanserin for treating disorders of sexual desire |
| US7025745B2 (en) * | 2002-10-07 | 2006-04-11 | Advanced Cardiovascular Systems, Inc. | Method of making a catheter balloon using a tapered mandrel |
| KR20060119971A (ko) | 2003-09-11 | 2006-11-24 | 제노포트 인코포레이티드 | Ｇａｂａ 유사체의 전구약물을 이용한 요실금의 치료및/또는 예방 |
| PT1677767E (pt) * | 2003-10-14 | 2011-10-13 | Xenoport Inc | Forma cristalina de análogo de ácido gama-aminobutírico |
| CA2584338C (en) | 2004-11-04 | 2013-08-06 | Xenoport, Inc. | Gabapentin prodrug sustained release oral dosage forms |
| ES2646326T3 (es) | 2005-08-03 | 2017-12-13 | Sprout Pharmaceuticals, Inc. | Uso de flibanserina en el tratamiento de la obesidad |
| WO2007027476A2 (en) * | 2005-08-26 | 2007-03-08 | Xenoport, Inc. | Treating premature ejaculation using gabapentin and pregabalin prodrugs |
| NL2000281C2 (nl) * | 2005-11-02 | 2007-08-07 | Pfizer Prod Inc | Vaste farmaceutische samenstellingen die pregabaline bevatten. |
| JP2009541443A (ja) | 2006-06-30 | 2009-11-26 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 尿失禁及び関連疾患の治療のためのフリバンセリン |
| WO2008073257A1 (en) * | 2006-12-08 | 2008-06-19 | Xenoport, Inc. | Use of prodrugs of gaba analogs for treating diseases |
| CA2673545A1 (en) | 2006-12-22 | 2008-07-03 | Recordati Ireland Limited | Combination therapy of lower urinary tract disorders with .alpha.2.delta. ligands and nsaids |
| US20080206332A1 (en) * | 2007-01-11 | 2008-08-28 | Kidney David J | Sustained release oral dosage forms of a prodrug of r-baclofen and methods of treatment |
| CL2008002693A1 (es) | 2007-09-12 | 2009-10-16 | Boehringer Ingelheim Int | Uso de flibanserina para el tratamiento de sintomas vasomotores seleccionados de sofocos, sudores nocturnos, cambios de estado de animo e irritabilidad |
| WO2009087682A2 (en) * | 2007-12-28 | 2009-07-16 | Intas Pharmaceuticals Limited | Stabilized injectable formulation of pregabalin |
| EP2250148B1 (en) * | 2008-01-25 | 2016-08-17 | XenoPort, Inc. | Crystalline form of calcium-salts of (3s)-aminomethyl-5-methyl-hexanoic acids and methods of use |
| CA2706575C (en) * | 2008-01-25 | 2015-07-14 | Xenoport, Inc. | Enantiomerically resolving acyloxyalkyl thiocarbonates used in synthesizing acyloxyalkyl carbamate prodrugs |
| US7868043B2 (en) | 2008-01-25 | 2011-01-11 | Xenoport, Inc. | Mesophasic forms of (3S)-aminomethyl-5-methyl-hexanoic acid prodrugs and methods of use |
| CA2686480A1 (en) | 2008-12-15 | 2010-06-15 | Boehringer Ingelheim International Gmbh | New salts |
| NZ594648A (en) * | 2009-03-03 | 2013-12-20 | Xenoport Inc | Sustained release oral dosage forms of an r-baclofen prodrug |
| WO2011109403A1 (en) * | 2010-03-01 | 2011-09-09 | Xenoport, Inc. | Use of (3r)-4-{[(1s)-2-methyl-1- (2-methylpropanoyloxy)propoxy]carbonylamino}-3-(4-chlorophenyl) butanoic acid for treating urinary incontinence |
Family Cites Families (87)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2996431A (en) * | 1953-12-16 | 1961-08-15 | Barry Richard Henry | Friable tablet and process for manufacturing same |
| US3402240A (en) * | 1957-06-25 | 1968-09-17 | Pfizer & Co C | Medicinal tablet and process of making same |
| US3139383A (en) * | 1961-06-26 | 1964-06-30 | Norton Co | Encapsulated time release pellets and method for encapsulating the same |
| US3962414A (en) * | 1972-04-27 | 1976-06-08 | Alza Corporation | Structured bioerodible drug delivery device |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3811444A (en) * | 1972-12-27 | 1974-05-21 | Alza Corp | Bioerodible ocular device |
| US3916899A (en) * | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| DE2336218C3 (de) * | 1973-07-17 | 1985-11-14 | Byk Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz | Orale Arzneiform |
| US3992518A (en) * | 1974-10-24 | 1976-11-16 | G. D. Searle & Co. | Method for making a microsealed delivery device |
| GB1478759A (en) * | 1974-11-18 | 1977-07-06 | Alza Corp | Process for forming outlet passageways in pills using a laser |
| DE2460891C2 (de) * | 1974-12-21 | 1982-09-23 | Gödecke AG, 1000 Berlin | 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel |
| US4093709A (en) * | 1975-01-28 | 1978-06-06 | Alza Corporation | Drug delivery devices manufactured from poly(orthoesters) and poly(orthocarbonates) |
| US4063064A (en) * | 1976-02-23 | 1977-12-13 | Coherent Radiation | Apparatus for tracking moving workpiece by a laser beam |
| US4079038A (en) * | 1976-03-05 | 1978-03-14 | Alza Corporation | Poly(carbonates) |
| US4066747A (en) * | 1976-04-08 | 1978-01-03 | Alza Corporation | Polymeric orthoesters housing beneficial drug for controlled release therefrom |
| US4070347A (en) * | 1976-08-16 | 1978-01-24 | Alza Corporation | Poly(orthoester) co- and homopolymers and poly(orthocarbonate) co- and homopolymers having carbonyloxy functionality |
| US4285987A (en) * | 1978-10-23 | 1981-08-25 | Alza Corporation | Process for manufacturing device with dispersion zone |
| US4200098A (en) | 1978-10-23 | 1980-04-29 | Alza Corporation | Osmotic system with distribution zone for dispensing beneficial agent |
| US4434153A (en) | 1982-03-22 | 1984-02-28 | Alza Corporation | Drug delivery system comprising a reservoir containing a plurality of tiny pills |
| US4421736A (en) * | 1982-05-20 | 1983-12-20 | Merrel Dow Pharmaceuticals Inc. | Sustained release diethylpropion compositions |
| US4721613A (en) * | 1982-12-13 | 1988-01-26 | Alza Corporation | Delivery system comprising means for shielding a multiplicity of reservoirs in selected environment of use |
| US4820523A (en) * | 1986-04-15 | 1989-04-11 | Warner-Lambert Company | Pharmaceutical composition |
| US4752470A (en) * | 1986-11-24 | 1988-06-21 | Mehta Atul M | Controlled release indomethacin |
| US4816263A (en) * | 1987-10-02 | 1989-03-28 | Alza Corporation | Dosage form for treating cardiovascular diseases comprising isradipine |
| US4853229A (en) * | 1987-10-26 | 1989-08-01 | Alza Corporation | Method for adminstering tiny pills |
| DE3928183A1 (de) * | 1989-08-25 | 1991-02-28 | Goedecke Ag | Lactamfreie cyclische aminosaeuren |
| US5827819A (en) * | 1990-11-01 | 1998-10-27 | Oregon Health Sciences University | Covalent polar lipid conjugates with neurologically active compounds for targeting |
| AU9137091A (en) | 1990-11-27 | 1992-06-25 | Northwestern University | Gaba and l-glutamic acid analogs for antiseizure treatment |
| US6197819B1 (en) * | 1990-11-27 | 2001-03-06 | Northwestern University | Gamma amino butyric acid analogs and optical isomers |
| US5698155A (en) * | 1991-05-31 | 1997-12-16 | Gs Technologies, Inc. | Method for the manufacture of pharmaceutical cellulose capsules |
| JP3856816B2 (ja) | 1992-05-20 | 2006-12-13 | ノースウェスターン ユニヴァーシティ | 抗発作治療用のｇａｂａ及びｌ−グルタミン酸類縁体 |
| US6287598B1 (en) * | 1993-05-28 | 2001-09-11 | Alza Corporation | Method for providing sustained antiepileptic therapy |
| EP0888325B1 (en) | 1996-02-07 | 2002-05-29 | Warner-Lambert Company | Novel cyclic amino acids as pharmaceutical agents |
| WO1997033859A1 (en) * | 1996-03-14 | 1997-09-18 | Warner-Lambert Company | Novel bridged cyclic amino acids as pharmaceutical agents |
| HU224720B1 (en) * | 1996-03-14 | 2006-01-30 | Warner Lambert Co | Novel substituted cyclic amino acid derivatives use as pharmaceutical agents |
| US6375987B1 (en) * | 1996-10-01 | 2002-04-23 | Gattefossé, S.A. | Process for the manufacture of pharmaceutical composition with modified release of active principle comprising the matrix |
| ATE361909T1 (de) | 1996-10-23 | 2007-06-15 | Warner Lambert Co | Substituierte gamma-aminobuttersäurederivate als arzneimittel |
| WO1999008670A1 (en) | 1997-08-20 | 1999-02-25 | Guglietta, Antonio | Gaba analogs to prevent and treat gastrointestinal damage |
| ATE323067T1 (de) | 1997-10-27 | 2006-04-15 | Warner Lambert Co | Zyklische aminosäuren und deren derivate als arzneimittel |
| SI1045839T1 (en) | 1997-12-16 | 2004-06-30 | Warner-Lambert Company Llc | Novel amines as pharmaceutical agents |
| CA2304967C (en) | 1997-12-16 | 2005-06-14 | Warner-Lambert Company | 4(3)substituted-4(3)-aminomethyl-(thio)pyran or -piperidine derivatives (=gabapentin analogues), their preparation and their use in the treatment of neurological disorders |
| CN1131855C (zh) | 1997-12-16 | 2003-12-24 | 沃尼尔·朗伯公司 | 1－取代－1－氨基甲基－环烷衍生物(=加巴喷丁类似物)、其制备及其在治疗神经病方面的用途 |
| WO1999061424A1 (en) | 1998-05-26 | 1999-12-02 | Warner-Lambert Company | Conformationally constrained amino acid compounds having affinity for the alpha2delta subunit of a calcium channel |
| FR2779651B1 (fr) * | 1998-06-16 | 2001-04-20 | Gattefosse Ets Sa | Procede pour la fabrication de comprimes a liberation prolongee de principe(s) actif(s) presentant une cinetique de dissolution d'ordre zero |
| US6171615B1 (en) | 1998-07-06 | 2001-01-09 | Gattefoss{acute over (e)} | Sustained release theophylline formulations, excipient systems and methods of production |
| US6245801B1 (en) | 1998-09-14 | 2001-06-12 | Warner-Lambert Company | Branched alkyl pyrrolidine-3-carboxylic acids |
| US6627771B1 (en) | 1998-11-25 | 2003-09-30 | Pfizer Inc | Gamma amino butyric and acid analogs |
| EP1031350A1 (en) | 1999-02-23 | 2000-08-30 | Warner-Lambert Company | Use of a gabapentin-analog for the manufacture of a medicament for preventing and treating visceral pain |
| EP1977745B1 (en) * | 1999-04-08 | 2010-04-07 | Warner-Lambert Company LLC | Treatment of incontinence |
| US6992109B1 (en) * | 1999-04-08 | 2006-01-31 | Segal Catherine A | Method for the treatment of incontinence |
| AU767119B2 (en) * | 1999-07-22 | 2003-10-30 | University Of Rochester | Method of treating symptoms of hormonal variation, including hot flashes |
| US6793934B1 (en) | 1999-12-08 | 2004-09-21 | Shire Laboratories, Inc. | Solid oral dosage form |
| GB2362646A (en) | 2000-05-26 | 2001-11-28 | Warner Lambert Co | Cyclic amino acid derivatives useful as pharmaceutical agents |
| IL152770A0 (en) | 2000-06-26 | 2003-06-24 | Warner Lambert Co | Gabapentin analogues for sleep disorders |
| GB2365425A (en) | 2000-08-01 | 2002-02-20 | Parke Davis & Co Ltd | Alkyl amino acid derivatives useful as pharmaceutical agents |
| EP1361847A2 (en) | 2000-10-06 | 2003-11-19 | Xenoport, Inc. | Bile-acid conjugates for providing sustained systemic concentrations of drugs |
| WO2002028881A1 (en) | 2000-10-06 | 2002-04-11 | Xenoport, Inc. | Bile-acid derived compounds for providing sustained systemic concentrations of drugs after oral administration |
| WO2002028411A1 (en) | 2000-10-06 | 2002-04-11 | Xenoport, Inc. | Compounds for sustained release of orally delivered drugs |
| US6683112B2 (en) * | 2000-10-24 | 2004-01-27 | Andrx Corporation | Gabapentin prodrugs and formulations |
| GB2368579A (en) | 2000-10-31 | 2002-05-08 | Parke Davis & Co Ltd | Azole pharmaceutical agents |
| AU2002239257A1 (en) | 2000-11-17 | 2002-06-03 | Xenoport, Inc. | Amino acid conjugates providing for sustained systemic concentrations of gaba analogues |
| US7232924B2 (en) * | 2001-06-11 | 2007-06-19 | Xenoport, Inc. | Methods for synthesis of acyloxyalkyl derivatives of GABA analogs |
| US7186855B2 (en) * | 2001-06-11 | 2007-03-06 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
| ATE540678T1 (de) * | 2001-06-11 | 2012-01-15 | Xenoport Inc | Prodrugs aus gaba-analoga, zusammensetzungen und ihre verwendungen |
| US6818787B2 (en) * | 2001-06-11 | 2004-11-16 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
| US8048917B2 (en) * | 2005-04-06 | 2011-11-01 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
| AU2002316237A1 (en) | 2001-06-13 | 2002-12-23 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Healt | Use of the parathroid hormone-2 (pth2) receptor to screen for agents to treat pain |
| US7109231B2 (en) * | 2001-08-09 | 2006-09-19 | Eli Lilly And Company | Cyclohept[b]indole derivatives |
| WO2003077902A1 (en) * | 2002-02-19 | 2003-09-25 | Xenoport, Inc. | Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof |
| WO2003099338A2 (en) | 2002-05-17 | 2003-12-04 | Xenoport, Inc. | Amino acid conjugates providing for sustained systemic concentrations of gaba analogues |
| WO2004053192A1 (en) | 2002-12-11 | 2004-06-24 | Xenoport, Inc. | Orally administered dosage forms of fused gaba analog prodrugs having reduced toxicity |
| WO2004052360A1 (en) | 2002-12-11 | 2004-06-24 | Xenoport, Inc. | Prodrugs of fused gaba analogs, pharmaceutical compositions and uses thereof |
| ES2288641T3 (es) * | 2002-12-20 | 2008-01-16 | Dynogen Pharmaceuticals Inc. | Metodo para tratar trastornos indoloros de la vejiga usando moduladores de canales del calcio de la subunidad alfa2-delta. |
| DE602004003172T2 (de) * | 2003-03-21 | 2007-09-27 | Dynogen Pharmaceuticals Inc., Waltham | Verfahren zur behandlung von erkrankungen der unteren harnwege mit antimuskarinika und mit modulatoren der alpha-2-delta untereinheit des kalziumkanals |
| JP2006522146A (ja) * | 2003-03-31 | 2006-09-28 | ゼノポート，インコーポレイティド | Ｇａｂａ類似体のプロドラッグを使用するのぼせの治療または予防 |
| WO2005010011A2 (en) * | 2003-07-15 | 2005-02-03 | Xenoport, Inc. | Methods of synthesis of acyloxyalkyl compounds |
| KR20110097942A (ko) * | 2003-08-20 | 2011-08-31 | 제노포트 인코포레이티드 | 아실옥시알킬 카르바메이트 프로드러그, 합성 및 사용 방법 |
| KR20060119971A (ko) | 2003-09-11 | 2006-11-24 | 제노포트 인코포레이티드 | Ｇａｂａ 유사체의 전구약물을 이용한 요실금의 치료및/또는 예방 |
| AU2004274002B2 (en) * | 2003-09-17 | 2011-04-28 | Arbor Pharmaceuticals, Llc | Treating or preventing restless legs syndrome using prodrugs of GABA analogs |
| PT1677767E (pt) * | 2003-10-14 | 2011-10-13 | Xenoport Inc | Forma cristalina de análogo de ácido gama-aminobutírico |
| EP2371815A1 (en) * | 2003-12-30 | 2011-10-05 | XenoPort, Inc. | Sythesis of acyloxyalkyl carbamate prodrugs and intermediates thereof |
| CA2584338C (en) * | 2004-11-04 | 2013-08-06 | Xenoport, Inc. | Gabapentin prodrug sustained release oral dosage forms |
| US20060222700A1 (en) | 2005-04-05 | 2006-10-05 | Groenewoud Pieter J | Tablet and capsule form of liquid active ingredient |
| EP1968542B1 (en) | 2005-12-16 | 2013-08-14 | Hanmi Science Co., Ltd. | Solid dispersion comprising an active ingredient having a low melting point and tablet for oral administration comprising same |
| US20080188562A1 (en) * | 2006-11-14 | 2008-08-07 | Noa Zerangue | Treating tinnitus using prodrugs of gabapentin and pregabalin |
| WO2008073257A1 (en) * | 2006-12-08 | 2008-06-19 | Xenoport, Inc. | Use of prodrugs of gaba analogs for treating diseases |
| US20080206332A1 (en) * | 2007-01-11 | 2008-08-28 | Kidney David J | Sustained release oral dosage forms of a prodrug of r-baclofen and methods of treatment |
-
2004
- 2004-09-13 KR KR1020067005033A patent/KR20060119971A/ko not_active Withdrawn
- 2004-09-13 CA CA002537837A patent/CA2537837A1/en not_active Abandoned
- 2004-09-13 WO PCT/US2004/029944 patent/WO2005025562A1/en not_active Ceased
- 2004-09-13 JP JP2006526389A patent/JP2007505149A/ja active Pending
- 2004-09-13 EP EP04788728A patent/EP1670451A4/en not_active Withdrawn
- 2004-09-13 US US10/940,884 patent/US7700652B2/en not_active Expired - Fee Related
- 2004-09-13 NZ NZ545884A patent/NZ545884A/en unknown
- 2004-09-13 AU AU2004272111A patent/AU2004272111A1/en not_active Abandoned
- 2004-09-13 MX MXPA06002731A patent/MXPA06002731A/es not_active Application Discontinuation
-
2006
- 2006-03-20 IL IL174409A patent/IL174409A0/en unknown
- 2006-04-10 NO NO20061625A patent/NO20061625L/no not_active Application Discontinuation
-
2010
- 2010-03-09 US US12/720,414 patent/US20100166825A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007505149A5 (https=) | ||
| US8101661B2 (en) | Polar hydrophilic prodrugs and non-standard amino acid conjugates of amphetamine and other stimulants and processes for making and using the same | |
| AU721190B2 (en) | Use of creatine analogues for the treatment of disorders of glucose metabolism | |
| JP2009538348A5 (https=) | ||
| CN1283994A (zh) | 使用氨基硫醇化合物治疗神经和肾疾病和治疗毒性的方法 | |
| CA2549717A1 (en) | Compositions and methods for treating diabetes | |
| BRPI0807157A2 (pt) | Pró-farmacos hidrófilos polares de anfetamina e outros estimulantes e processos para fabricação e uso dos mesmos | |
| JP7830540B2 (ja) | ｄ－アンフェタミン化合物、組成物、ならびにそれを作製および使用するためのプロセス | |
| US11613528B2 (en) | Small molecule inhibitors of shared epitope-calreticulin interactions and methods of use | |
| WO2017185087A1 (en) | Use of thyroid beta-agonists | |
| AU2017252122B2 (en) | Use of Thyroid beta-Agonists | |
| US20070167403A1 (en) | Remedy for spinal canal stenosis | |
| RU2006112549A (ru) | Лечение или предупреждение синдрома беспокойных ног с использованием пролекарств аналогов гамк | |
| US20060094664A1 (en) | Deoxycholic acid derivatives for the treatment of acute dysfunctions of portal and hepatic venous circulation | |
| KR100379155B1 (ko) | 새로운 진통제 조성물 | |
| Revill et al. | Gabapentin enacarbil | |
| ES2357245T3 (es) | Inhibidor de los pólipos intestinales. | |
| US6291441B1 (en) | Method of treating inflammatory bowel disorders | |
| BR122025010953A2 (pt) | Compostos de d-anfetamina, composição que compreende os mesmos, kit que compreende a dita composição e uso terapêutico dos ditos compostos | |
| HK40077785A (en) | D-amphetamine compounds, compositions, and processes for making and using the same | |
| JP2843944B2 (ja) | 利胆剤 | |
| HK40105778A (zh) | 包含酶可裂解的前药和萘莫司他的组合物及其使用方法 | |
| US20200338098A1 (en) | Conjoint Therapies with Inhibitors of Glucose Production | |
| WO2005056019A1 (ja) | 悪性黒色腫治療剤 | |
| JP2005534666A5 (https=) |